Xarelto® Injury Lawyers
Xarelto® (rivaroxaban) is one of the newest blood thinner medications on the market, and it has been linked to serious and uncontrollable internal bleeding events. Xarelto is more dangerous than other traditional blood thinner medications because it does not have an antidote to reverse the internal bleeding. Common injuries associated with Xarelto include:
- Gastrointestinal bleeding
- Brain hemorrhage
Xarelto is manufactured by Janssen Pharmaceutical and is co-marketed by Bayer Healthcare and Johnson & Johnson. The drug has been approved by the U.S. Food and Drug Administration (FDA) for many different indications, including:
- Prevention of blood clots in patients who recently underwent hip or knee replacement surgery (approved July 2011);
- Prevention of stroke in patient with atrial fibrillation (an irregular heart beat) (approved November 2011);
- Treatment of deep vein thrombosis (DVT) and treatment of pulmonary embolism (PE) (approved November 2012); and
- Reduction in the risk of reoccurrence of DVT and PE (approved November 2012).
Xarelto was introduced to the market after the FDA initially approved a similar blood thinner medication Pradaxa® (Dabigatran) in October 2010. Xarelto and Pradaxa are used to treat the same conditions, but they work in different ways. Xarelto inhibits the protein Factor Xa, which interrupts the blood-clotting process and prevents another protein, thrombin, from forming. Pradaxa instead directly prevents thrombin from forming to interrupt the coagulation process. While these drugs are functionally different, both anticoagulants have been linked to causing uncontrollable internal bleeding. Lawsuits have been filed against the manufacturers of both drugs based in part on the company’s failure to adequately warn users of the increased risks of suffering bleeding events.
Xarelto has been a popular choice among doctors and patients because it does not require strict diet changes or frequent monitoring to determine proper dosage levels. However, since its approval by the FDA, Xarelto has exceeded Pradaxa in the number of reported adverse events, including serious and irreversible bleeding events. The Institute for Safe Medication Practices (ISMP) reports that in 2013, the FDA received 680 serious adverse event reports from individuals who alleged to have suffered adverse complications while taking Xarelto, while only 528 serious adverse events were reported for Pradaxa. The FDA’s Adverse Event Reporting System (FAERS) is the core establishment for postmarket safety surveillance, a mechanism through which the FDA can monitor the safety and effectiveness of a drug once it hits the market.
In December 2014, the growing number of Xarelto claims filed in courts throughout the country were consolidated for coordinated pretrial purposes before the U.S. District Judge Eldon Fallon sitting in the Eastern District of Louisiana (In re: Xarelto Products Liability Litigation, MDL 2592). The Xarelto lawsuits allege that the manufacturer failed to warn patients and physicians about the risks of uncontrollable and often fatal internal bleeding events associated with Xarelto use. The attorneys at Schlichter Bogard & Denton play a key role in the Xarelto litigation, just as they did in the nationwide litigation involving Pradaxa which was settled with the drug’s manufacturer, Boehringer Ingelheim, for $650 million after two years of litigation. In the In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL 2385, Roger C. Denton of Schlichter Bogard & Denton was appointed by the Court to serve in a Lead Counsel role and was instrumental in facilitating the settlement.
As a result of Roger’s strong leadership in the Pradaxa litigation, he has also earned an appointment by Judge Fallon to serve in a leadership role in the Xarelto MDL. Judge Fallon appointed Roger C. Denton to serve in the Xarelto MDL on the Plaintiffs’ Steering Committee, a committee comprised of experienced attorneys to spearhead the litigation. Roger also serves as co-chair of the Discovery Committee and is responsible for managing the discovery strategies on behalf of plaintiffs in the litigation. Kristine Kraft and Ashley Brittain-Landers also serve on the Discovery Committee and Science Committee.
If you or someone you know has taken Xarelto and suffered any of the injuries associated with the drug, you may be entitled to compensation. Contact our experienced trial attorneys for a free and confidential case consultation.
Schlichter Bogard & Denton - Phone: 1-800-873-5297